259 related articles for article (PubMed ID: 36323073)
1. Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy.
Lu Q; Chen R; Du S; Chen C; Pan Y; Luan X; Yang J; Zeng F; He B; Han X; Song Y
Biomaterials; 2022 Dec; 291():121871. PubMed ID: 36323073
[TBL] [Abstract][Full Text] [Related]
2. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
3. Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization.
Fierro J; DiPasquale J; Perez J; Chin B; Chokpapone Y; Tran AM; Holden A; Factoriza C; Sivagnanakumar N; Aguilar R; Mazal S; Lopez M; Dou H
Sci Rep; 2022 Feb; 12(1):2417. PubMed ID: 35165339
[TBL] [Abstract][Full Text] [Related]
4. Precisely Activating cGAS-STING Pathway with a Novel Peptide-Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy.
Xing Y; Peng A; Yang J; Cheng Z; Yue Y; Liu F; Li F; Liu Y; Liu Q
Adv Sci (Weinh); 2024 Apr; 11(15):e2309583. PubMed ID: 38233164
[TBL] [Abstract][Full Text] [Related]
5. Bioorthogonal Reaction-Mediated Tumor-Selective Delivery of CRISPR/Cas9 System for Dual-Targeted Cancer Immunotherapy.
Yang J; Yang K; Du S; Luo W; Wang C; Liu H; Liu K; Zhang Z; Gao Y; Han X; Song Y
Angew Chem Int Ed Engl; 2023 Sep; 62(37):e202306863. PubMed ID: 37485554
[TBL] [Abstract][Full Text] [Related]
6. Genome editing of PD-L1 mediated by nucleobase-modified polyamidoamine for cancer immunotherapy.
Wei S; Shao X; Liu Y; Xiong B; Cui P; Liu Z; Li Q
J Mater Chem B; 2022 Feb; 10(8):1291-1300. PubMed ID: 35141737
[TBL] [Abstract][Full Text] [Related]
7. Reprogramming the Tumor Microenvironment through Second-Near-Infrared-Window Photothermal Genome Editing of PD-L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy.
Tang H; Xu X; Chen Y; Xin H; Wan T; Li B; Pan H; Li D; Ping Y
Adv Mater; 2021 Mar; 33(12):e2006003. PubMed ID: 33538047
[TBL] [Abstract][Full Text] [Related]
8. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Antitumor Effect on Bladder Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout.
Zhen S; Lu J; Chen W; Zhao L; Li X
Hum Gene Ther; 2018 Dec; 29(12):1352-1363. PubMed ID: 30457360
[TBL] [Abstract][Full Text] [Related]
10. Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.
Xu Y; Chen C; Guo Y; Hu S; Sun Z
Front Immunol; 2022; 13():848327. PubMed ID: 35300341
[TBL] [Abstract][Full Text] [Related]
11. Carbon ion irradiation induces DNA damage in melanoma and optimizes the tumor microenvironment based on the cGAS-STING pathway.
Guo Y; Shen R; Wang F; Wang Y; Xia P; Wu R; Liu X; Ye W; Tian Y; Wang D
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6315-6328. PubMed ID: 36745223
[TBL] [Abstract][Full Text] [Related]
12. A carrier-free multiplexed gene editing system applicable for suspension cells.
Ju A; Lee SW; Lee YE; Han KC; Kim JC; Shin SC; Park HJ; EunKyeong Kim E; Hong S; Jang M
Biomaterials; 2019 Oct; 217():119298. PubMed ID: 31280073
[TBL] [Abstract][Full Text] [Related]
13. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
14. HSP70-Promoter-Driven CRISPR/Cas9 System Activated by Reactive Oxygen Species for Multifaceted Anticancer Immune Response and Potentiated Immunotherapy.
Zhao L; Li D; Zhang Y; Huang Q; Zhang Z; Chen C; Xu CF; Chu X; Zhang Y; Yang X
ACS Nano; 2022 Sep; 16(9):13821-13833. PubMed ID: 35993350
[TBL] [Abstract][Full Text] [Related]
15. Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells.
Lin Y; Wilk U; Pöhmerer J; Hörterer E; Höhn M; Luo X; Mai H; Wagner E; Lächelt U
Small; 2023 Jan; 19(2):e2205318. PubMed ID: 36399647
[TBL] [Abstract][Full Text] [Related]
16. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC.
Li K; Gong Y; Qiu D; Tang H; Zhang J; Yuan Z; Huang Y; Qin Y; Ye L; Yang Y
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002188
[TBL] [Abstract][Full Text] [Related]
17. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy.
Li A; Yi M; Qin S; Song Y; Chu Q; Wu K
J Hematol Oncol; 2019 Apr; 12(1):35. PubMed ID: 30935414
[TBL] [Abstract][Full Text] [Related]
18. Dual-Responsive Core-Shell Tecto Dendrimers Enable Efficient Gene Editing of Cancer Cells to Boost Immune Checkpoint Blockade Therapy.
Liu J; Li G; Guo H; Ni C; Gao Y; Cao X; Xia J; Shi X; Guo R
ACS Appl Mater Interfaces; 2023 Mar; 15(10):12809-12821. PubMed ID: 36853989
[TBL] [Abstract][Full Text] [Related]
19. A homologous-targeting cGAS-STING agonist multimodally activates dendritic cells for enhanced cancer immunotherapy.
Wang P; Wang Y; Li H; Wang M; Wang Y; Wang X; Ran L; Xin H; Ma J; Tian G; Gao W; Zhang G
Acta Biomater; 2024 Mar; 177():400-413. PubMed ID: 38336268
[TBL] [Abstract][Full Text] [Related]
20. Lovastatin/SN38 co-loaded liposomes amplified ICB therapeutic effect via remodeling the immunologically-cold colon tumor and synergized stimulation of cGAS-STING pathway.
Yang Y; Qi J; Hu J; Zhou Y; Zheng J; Deng W; Inam M; Guo J; Xie Y; Li Y; Xu C; Deng W; Chen W
Cancer Lett; 2024 Apr; 588():216765. PubMed ID: 38408604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
